Insider Selling: BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Sells 1,597 Shares of Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Aby J. Mathew sold 1,597 shares of the company’s stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $25.00, for a total transaction of $39,925.00. Following the sale, the executive vice president now directly owns 260,601 shares of the company’s stock, valued at $6,515,025. This represents a 0.61 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

BioLife Solutions Stock Performance

BioLife Solutions stock opened at $25.00 on Friday. The business has a 50 day moving average of $26.59 and a 200-day moving average of $25.49. BioLife Solutions, Inc. has a 1 year low of $14.84 and a 1 year high of $29.55. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.78 and a quick ratio of 1.78. The company has a market capitalization of $1.18 billion, a P/E ratio of -23.58 and a beta of 2.04.

BioLife Solutions (NASDAQ:BLFS) last released its quarterly earnings data on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.32. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. The company had revenue of $22.71 million during the quarter, compared to the consensus estimate of $21.73 million. During the same quarter in the prior year, the firm posted ($0.21) earnings per share. On average, equities research analysts predict that BioLife Solutions, Inc. will post -0.3 earnings per share for the current year.

Institutional Trading of BioLife Solutions

Institutional investors have recently added to or reduced their stakes in the stock. State Street Corp boosted its holdings in BioLife Solutions by 7.3% in the third quarter. State Street Corp now owns 1,412,316 shares of the medical equipment provider’s stock valued at $35,364,000 after acquiring an additional 95,788 shares during the last quarter. Geode Capital Management LLC boosted its holdings in BioLife Solutions by 2.2% in the third quarter. Geode Capital Management LLC now owns 842,771 shares of the medical equipment provider’s stock valued at $21,107,000 after acquiring an additional 18,473 shares during the last quarter. The Manufacturers Life Insurance Company boosted its holdings in BioLife Solutions by 40.8% in the third quarter. The Manufacturers Life Insurance Company now owns 19,463 shares of the medical equipment provider’s stock valued at $487,000 after acquiring an additional 5,638 shares during the last quarter. Barclays PLC boosted its holdings in BioLife Solutions by 20.1% in the third quarter. Barclays PLC now owns 64,423 shares of the medical equipment provider’s stock valued at $1,613,000 after acquiring an additional 10,803 shares during the last quarter. Finally, D.A. Davidson & CO. bought a new stake in BioLife Solutions in the third quarter valued at approximately $1,018,000. 93.24% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on BLFS shares. Northland Securities upped their price objective on shares of BioLife Solutions from $28.00 to $31.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 8th. Benchmark reissued a “buy” rating and set a $30.00 target price on shares of BioLife Solutions in a research note on Thursday, December 19th. HC Wainwright boosted their target price on BioLife Solutions from $27.00 to $30.00 and gave the stock a “buy” rating in a research note on Thursday, March 6th. Finally, KeyCorp boosted their target price on BioLife Solutions from $30.00 to $33.00 and gave the stock an “overweight” rating in a research note on Friday, December 13th. One research analyst has rated the stock with a sell rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $29.86.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.